In the last 10 years, microRNAs (miRNAs) have emerged as critical regulators of numerous physiological and pathological mechanisms [1-2], including cardiac and vascular smooth muscle cell (VSMC) plasticity [3-5]. These small molecules (approx. 20 to 25 nucleotides) comprise a novel and abundant class of endogenous interfering RNAs. More than 1 500 miRNAs are now listed by dedicated internet databases such as miRBase, Tarbase, MicroRNA.org or miRdb (See sub-chapter II for URL adresses). They are transcribed and matured, in a process known as miRNA biogenesis  which starts with the transcription of a larger RNA product, called pri-miRNA, by the RNA polymerase II in the vast majority of cases. Pri-miRNA, which is a few hundred to a few thousand nucleotides long, is then submitted to cleavage in the nucleus by a specific RNase III (Drosha) and its protein partner, DiGeorge syndrome critical region 8 (DGCR8), near the base of the miRNA hairpin stem. This process releases a pre-miRNA hairpin (of approx. 60 to 70 nt). The pre-miRNA is then released in the cytoplasm where it is recognized and cleaved within its stems by the Dicer RNase III and its protein partners. This results in a double stranded RNA, known as the miRNA/miRNA* duplex (approx. 22 bp). This complex is unwound to single strands. One strand (guiding strand / mature miRNA) is incorporated in the RNA-induced-silencing complex (
Determining how the RISC complex carries a specific miRNA to its target mRNAs, and thus regulates gene expression, remains an intense field of research. The most important feature in the miRNA sequence is a short but critical region called the seed sequence, which is only 7 nts long, and most of the times, located in nucleotides in positions 2 to 8 of the miRNA. The base-pairing uses canonical Watson-Crick complementarity. Conversely, this small stretch of nucleic acids is a useful tool to classify miRNA into families based on shared seed sequences. Since the miRNA seed is so short, each miRNA can potentially bind hundreds of target mRNAs when one considers the large number of possible binding sites in mRNA regulatory sequences. This is one of the reasons why one single miRNA can regulate the expression of multiple target genes, by binding as many as several hundreds of mRNA targets. This clearly shows the role of these small RNAs in the intricate tapestry of gene regulations. Another, foremost reason for this complexity is that miRNAs, outside of the seed region, bind their mRNA targets mostly as imperfect complements. Similarly, one mRNA can be regulated by several miRNAs. All this further explains how the 1 500 miRNAs known to date are able to regulate the expression of approximately one third of the human genes. Thus, microRNAs are likely to impact multiple mechanisms of gene regulation and developmental pathways, by using extensive regulatory gene expression networks [1-2].
The current paradigm states that miRNAs act mostly by inhibiting the translation of their target mRNAs, rather than by inducing their degradation. Bartel’s team has however recently challenged that view by showing that, in a vast majority of cases, mammalian microRNAs act by destabilizing their target mRNAs and by decreasing their levels . No matter the case, a wide consensus agrees that miRNAs are posttranscriptional regulators which bind to their target mRNAs, mostly in their 3’ Untranslated Region (UTR). Note, however, that recent unbiased studies have shown that, in some particular cases, miRNAs bind the coding region or 5’UTR of respective target mRNAs ([9-11].
The miRNA nomenclature is remarkably standardized and straightforward : the prefix "mir" is followed by a dash and an assigned number, reflecting the prevalence of discovery, to experimentally confirmed miRNAs. Gene is referred to in italic, eg
Mature miRNA sequences and pathways are remarkably preserved throughout phylogeny. Also, the evolutionary complexity of multicellular organisms positively correlates with the number of miRNA genes, their expression, and the diversity of their targets . This remarkable conservation is used by most miRNA target prediction algorithms. These dedicated softwares use a standardized method to evaluate interactions between miRNAs and their specific target mRNAs based on (1) complementarity between mRNA 3’ UTR and miRNA seed sequence and (2) the degree of conservation of miRNA across species (see subchapter 2 for url adresses). The end result is straightforward: the higher the conservation, the higher the score given.
2. Current methods for studying miRNAs: Functional analysis
Various techniques have been developed over the last decade to quantify the expression of miRNAs and study their function (extensively reviewed in ). Figure 2 exposes the most widely used methods. Northern blotting was first used to quantify miRNAs, but this tedious technique, relying on radioactive labeling, was rapidly replaced by the much more convenient qRT-PCR. Two interchanging chemistries can be used for qPCR: (1) Sybr Green, which is often associated with a modified oligo(dT) technique, and the adjunction of an universal primer for reverse transcription which enables reverse transcription of all transcripts within an RNA sample; therefore, target miRNA and normalizing mRNA can be analyzed from the same RT reaction; or (2) Taqman chemistry, in association with the use of stem-loop miRNA-specific RT primers to produce cDNA, with the advantage of additional specificity. Both give accurate results. Each method has its own assets and setbacks. Technically speaking, the modified oligo(dT) method requires only a single RT reaction to reverse transcribe both miRNA and its target mRNAs and is less time consuming. Both techniques have been optimized and developed to screen most of known miRNAs in one experiment. Indeed, analysis of high-throughput miRNA expression remains a challenge since the number of miRNAs continues to increase with
Over-expressing or inhibiting miRNA activity, using RNA constructs, and examining the resulting phenotypic effects is crucial for understanding microRNA involvement, both
Finally, classic knock-out genetic strategies can be applied to miRNA genes . MiRNA-processing proteins such as Dicer, Dgcr8, Drosha or Ago2 are essential for viability in mice. Knock-out mice individually lacking these key miRNA-processing genes die during early gestation with severe developmental defects, including in vessels and heart. However, conditional murine knockout of these genes have been developed recently and offer valuable tools to study miRNA importance, including in the cardiac organ. Also, one can obtain animals models totally devoid of the miRNA of interest. We describe below the interesting example of mice knock-outed of the most widely expressed vascular miRNAs, miR-143 and miR-145 (see subchapter III, [18-20]).
Websites are dedicated to identification of microRNA gene targets, and experimental validation of these
3. MicroRNAs are implicated in the pathophysiology of vascular smooth muscle cells
VSMCs are not terminally differentiated cells like skeletal and cardiac muscle cells. They have a remarkable plasticity which allows them to undergo phenotypic modulation inducing a switch from a “synthetic” to a “contractile” phenotype, in response to physiological and pathological environmental cues. On one hand, vascular injury or growth factors like PDGF provoke VSMC dedifferentiation which, as a consequence, transdifferentiates the cells into a highly migratory and proliferative (“synthetic”) phenotype necessary for vascular repair or angiogenesis. On another hand, Transforming Growth Factor-β (TGF-β) and its related family member Bone Morphogenetic Protein 4 (BMP4) promote differentiation into a less migratory and less proliferative phenotype known as the “contractile” phenotype. This VSMC phenotypic modulation, called transdifferentiation, is characterized by significant changes in cellular gene expression pattern. In particular, high expression of VSMC-specific genes, such as smooth muscle α-actin (SMαA), calponin1 (CNN), and SM22α (SM22) are associated with the contractile phenotype. Transcription of contractile genes is regulated by SRF through a DNA sequence motif known as the CArG box (CC(A/T)6GG) which is present in the promoter of VSMC-specific genes. A coactivator (and binding partner) of SRF, myocardin, activates VSMC expression of key contractile genes ([22-23].
The recent emerging role of miRNAs in gene expression regulation
3.1. The miR-143/145 cluster
The bicistronic unit which encodes miR-143 and miR-145 is critical for maintaining the VSMC contractile phenotype. For example, miR-143 and miR-145 are down-regulated in synthetic VSMCs [19-20] when VSMC dedifferentiation is induced by PDGF and during neointimal formation . On the opposite, TGFβ1 (Transforming Growth Factor 1), a strong activator of VSMC differentiation, stimulates both miRNAs expression in a dose- and time-dependent manner . The transcription of miR-143/145 is under the control of two independent signaling pathways: SRF/myocardin/Nkx2.5 and Jag-1/Notch signaling . The expression of miR-143/145 is drastically reduced in several models of vascular disease: carotid artery ligation injury in mouse, carotid balloon-injury in rat, and ApoE Knock-out mice . In miR-143 or miR-145 KO mice, abnormal vascular tone and reduced contractile activity have been detected but VSMCs are functional . Moreover, miR-143/145 levels are decreased in aortas from patients with aortic aneurism and lower circulating levels are detected in the serum of patients with coronary artery disease [20-22]. Overexpression of miR-145 induced lower neointima formation in balloon-injuried arteries .
Dimmeler and colleagues showed recently an example of vesicle-mediated miRNA transfer between human vascular endothelial cells and human aortic SMCs . Blood vessels exposed to laminar blood flow undergo high shear stress. It is known that under shear stress conditions vascular endothelial cells overexpress the transcription factor Krüppel-like factor 2 (KLF2) which in turn induces up-regulation of miR-143 and miR-145. MiR-143/145 are transported in extracellular vesicles such as exosomes and they reduced the expression of miR-143 and miR-145 specific targets in co-cultured VSMCs. Additionally, the authors showed that extracellular vesicles derived from KLF2-expressing endothelial cells decrease atherosclerotic lesion formation in the ApoE KO mice kept on a high fat diet .
3.2. MiR-21, miR-221, and miR-222
In contrast to miR-143/145, miR-21, miR-221, and miR-222 are up-regulated in neointimal lesions.
TGF-β and its related family member BMP4 promote contractile gene expression and VSMC differentiation. Interestingly, they induce the transcription of the miR-143/145 cluster and promote also an increased expression of miR-21 post-transcriptionally. The critical target of miR-21 that is down-regulated in this process is programmed cell death 4 . As a consequence, miR-21 induces VSMCs transdifferentiation to the contractile phenotype in response to BMP4 and TGFβ . Additionally, miR-21 promotes VSMC proliferation and reduces apoptosis . These miR-21 actions were confirmed in balloon-injured rat carotid arteries . Moreover, knock-down of mir-21 using antisense oligonucleotides (antogomiRs) in the rat decreases vascular remodeling following balloon injury in carotid arteries . Although an increase in differentiation is usually coupled to a decrease in proliferation, this is not necessarily the case in VSMCs. MiR-21 indeed targets a diverse set of genes and mediates differential biological outcomes depending on the cellular context .
4. MicroRNAs are implicated in the pathophysiology of cardiac muscle cells
Cardiovascular pathologies represent the prevalent causes of human morbidity and mortality in the Western hemisphere. As a consequence, a vast number of research groups consider that studying heart molecular and cellular characteristics is a major step in order to develop novel diagnostic and therapeutic strategies and to counteract cardiovascular diseases. It is now clear that miRNAs are an important part of the complex transcriptional and posttranscriptional regulatory circuit essential for the homeostasis of the cardiac tissue. They are powerful modulators in virtually all aspects of cardiac biology, from cardiac development to cardiomyocyte survival and hypertrophy, which we will now describe in more detail in this subchapter.
In the recent literature, more than a hundred microRNAs have been described as stably expressed in the cardiac tissue [36-38]. However, the vast majority (90%) of these miRNAs are represented by no more than 18 miRNAs in the mature murine organ. Even more remarkable is the fact that all these 18 miRNAs show an altered expression in pathological conditions, including coronary artery diseases and cardiomyopathies. Interestingly, it has been shown that a strong characteristic of these various models of cardiovascular disorders is the re-expression of a fetal cardiac miRNA program. This miRNA expression will finally trigger the over-expression of several fetal proteins, such as the atrial and brain natriuretic factor genes and the fetal isoform of the β-Myosin Heavy Chain gene (βMHC). Exploring further how miRNAs regulate gene expression in the heart will thus provide us with unique mechanistic insights into cardiac diseases. We will now describe in further details the miRNAs which have been the most implicated in the process. See Figure 3B for a pictorial representation of their roles in cardiac muscle.
4.1. Anti-hypertrophic miRNAs
Muscle miRNAs, such as miR-1 and miR-133, are integrated into myogenic regulatory networks: their expression is under the transcriptional and posttranscriptional control of myogenic factors, and they in turn have widespread control of the muscle gene expression program. Recent studies demonstrated that both miR-1 and miR-133 are significantly downregulated in hypertrophic and failing hearts. They play major roles in the development of cardiac hypertrophy, and have thus been nicknamed anti-hypertrophic miRNAs. In addition, miR-1 and the related miRNA miR-133 arise from a common precursor RNA which is regulated by the transcription factors Serum Response Factor (SRF) and Myocyte Enhancer Factor 2 (MEF2, ), which clearly suggest their importance in an intricate cardiac regulatory network.
The mature miR-1 transcript is the product of two genes, miR-1-1 and miR1-2, and it is now proven that its elevation induces arrhythmia in cardiac disease states. Its expression is specific for both cardiac and skeletal muscle. Overexpression of mature miR-1 in rat exacerbates cardiac arrhythmia whereas its knock-down by an antagomiR in the same animal, in the infarcted heart relieves arrhythmogenesis . MiR-1 is also overexpressed in individuals with coronary artery disease. Part of miR-1 action is mediated by down regulation of connexin 43 and the inward rectifier K channel (Kir2.1, ). Another important role of miR-1 is to modulate cardiac excitation–contraction coupling by selectively increasing phosphorylation of the L-type and RyR2 channels
There are three known
4.2. Pro-hypertrophic miRNAs
The role of mir-21 in cardiac modeling and pathophysiology is clearly controversed. MiR-21 inhibition by antagomir strategies was first reported as causing an alleviation of murine cardiac hypertrophy [38,45]. A divergence arose when the first team attributed this pro-hypertrophic effect to an effect on cardiomyocytes  whereas the second team claimed the primary site of miR-21 action was actually cardiac fibroblasts . In contrast to both team results, Cheng et al.  reported that miR-21 was indeed increased by fourfold in hypertrophic mouse hearts, but that modulating miR-21
The human miR-29 family of microRNAs is encoded by two gene clusters. As a consequence, three matures members exist: miR-29a, miR-29b, and miR-29c. In this instance, the miR-29 family has been shown to be expressed in both cardiac fibroblasts and cardiomyocytes . In these cell types, sixteen of their targets are extracellular matrix genes. This clearly shows a striking example of a single microRNA mature sequence which is capable to target a large group of functionally related genes. As a consequence, miR-29 expression induces strong antifibrotic effects in heart and other tissues. MiR-29s have also been shown to be pro-apoptotic and involved in cell differentiation. Acute myocardial infarction due to coronary artery occlusion also results in a decrease of the expression of the miR-29 family in the region of the fibrotic scar . Using up- and down-regulation of miR-29, the same authors showed that this miRNA regulates the expression of collagens, and as a result the fibrotic response. Finally, the miR-29 family has also been shown to down-regulate elastin and other extracellular matrix (ECM) genes implicated in elastogenesis . Jones et al.  have examined miRNA expression using qPCR in aortic tissue collected from patients with ascending thoracic aortic aneurysm and shown that miR-29a expression is correlated with cardiac tissue proteolytic degradation and aortic size. These last results show the interest of determining specific miRNA levels in human diagnostic.
Another miRNA of interest in the cardiac field of investigation is miR-208a, which is expressed strictly in the heart. Mir-208a overexpression in transgenic mice induces hypertrophic growth of the cardiac muscle and induces arrhythmias. This hypertrophic growth is concomitant with fibrosis and a decrease of contractility, which results from down-regulation of the faster isoform, α-myosin heavy chain (α-MHC) and up-regulation of the fetal specific, slower isoform, β-MHC [51-52]. Thus, cardiac-speciﬁc overexpression of miR-208a induces cardiac remodeling and regulates the expression of hypertrophic proteins, including β-MHC. Conversely, the same authors showed that genetic deletion of miR-208a in mouse induces a decrease of β-MHC. Additionally, miR-208 targets other proteins, such as thyroid hormone-associated protein 1 and myostatin 2, which are both inhibitors of muscle growth and hypertrophy, with for final consequence hypertrophic cardiac growth. MiR-208a is also strongly up-regulated in the diseased human heart as detected in biopsies from patients afflicted with myocardial infarction . Also, miR-208a is not detected in plasma from healthy patients, but is raised to a detectable level as soon as 1 h after coronary artery occlusion . This result is important, since it clearly shows that, at least for this miRNA, plasma levels reflect tissue amounts, and thus that miRNA are strong candidates as non-invasive biomarkers (see subchapter VI for more information on this topic).
5. The miRNA regulators: Who watches the watchmen?
Expressional patterns of miRNAs vary according to organs and their developmental stages. Indeed, several transcriptional and post-transcriptional processes control the levels of mature miRNAs. The study of these regulatory mechanisms is still in its very early steps. We will review here what is known, starting with other non-coding RNAs which are as long as miRNAs are short, we will proceed with transcription factors, and finally explore how cells are able to communicate with each other, using microRNAs.
In the last few years, it has been shown that long non-coding RNAs act as miRNA sponges and/or competing endogenous RNAs, are able to regulate miRNA function by binding complementarily with them, thus competing with their dedicated mRNAs targets, and thereby to impose an additional level of post-transcriptional regulation. Little is known about the mechanisms of action of these exciting new regulatory RNAs in muscle cells. A groundbreaking result came from Cesana et al : they have identified a long non coding RNA, called linc-MD1, in the skeletal muscle. linc-MD1 is stably expressed in mouse and human myoblasts, and controls the myogenesis program by binding, and thus “sponging” two instrumental miRNAs, miR-133 and miR-135, which in turn regulate transcription factors that activate muscle-specific gene expression. By “inhibiting the inhibitors”, linc-MD1 accelerates myogenesis. Interestingly, this RNA’s expression is strongly reduced in Duchenne muscular dystrophy, a genetic disorder which is characterized by a drastic reduction of myoblasts. No equivalent of linc-MD1 has yet been described in smooth muscle biogenesis or in cardiogenesis but one can strongly guess that they will be identified in the forseeable future.
Several transcription factors have been characterized as miRNA regulators in smooth, cardiac and skeletal muscle cells, thus revealing novel mechanisms underlying VSMC differentiation. Myocardin is the best characterized in VSMCs and cardiac cells . Myocardin, with its co-activator Serum Response Factor (SRF), is a cardiac- and muscle specific trans-acting protein, and a master regulator of the smooth muscle phenotype. It has been shown that this transcription factor regulates several miRNAs in VSMCs. It induces miR-1 expression, which in turn inhibits VSMC proliferation, and increases their differentiation, by targeting Pim-1, a serine/threonine kinase . Similarly, myocardin represses versican, a chondroitin sulfate proteoglycan of the extra-cellular matrix that is produced by synthetic VSMCs and promotes VSMC migration and proliferation, by inducing the expression of miR-143, a miR instrumental in VSMC differentiation . SRF has been shown to regulate the expression of several mIRs, including miR-1, miR-133a and miR-21 . Interestingly, myocardin co-activator SRF regulates microRNA biogenesis, specifically the transcription of pri-microRNA, thereby affecting the mature microRNA level, by binding to the proximal promoter region of miR genes. Transforming Growth Factor-β1 (TGFβ1), another known stimulus capable of inducing VSMC differentiation, has also been shown to induce both miR-143 and miR-145 in human coronary artery SMCs . We have already discussed the importance of transcription factors SRF and MEF4 in the regulation of miR-1 and miR-133 (see subchapter 5). Finally, although skeletal muscle is outside of the topic of this chapter, it is interesting to note that another important muscle-specific transcription factor, MyoD, impacts miR-1 and miR-206 expressions, with strong consequences on myoblast apoptosis levels . Although it has not been shown yet, one can speculate that similar systems exist in smooth muscle and cardiac muscle cells.
Decay mechanisms affecting miRNAs in order to regulate their expression are not well understood. However, new notions have recently been put to the forefront: it seems that changes in cellular density and cell adhesion mechanisms affect rapidly miRNAs expression . When cells are grown at low density or after cell splitting, some miRNAs are rapidly degraded while others remain unaffected. This rapid, and yet unexplained, degradation of persistent regulatory molecules such as miRNAs may facilitate cellular plasticity and remodeling in response to various stresses.
Wang et al.  have recently shown that several human cell lines from various origins (glioblastoma, hepatocytes, lung bronchial epithelium, pulmonary fibroblasts, alveolar basal epithelial cells) actively release miRNAs in a short time period of time (approx. 1 h) after serum deprivation. Thus, one can hypothesize that, at least some, exported miRNAs are used for cell-to-cell communication. More studies will of course be needed to determine exactly how miRNAs are specifically targeted to relevant target cells, and what information is transduced. It will also be important to determine why evolution has selected several different means of transportation for miRNAs: protein complexes, exosomes, Microvesicles, High Density Lipoprotein (HDL) or apoptotic bodies (Figure 4). For example, miRNA complexed with proteins, could be targeted to specific cell surface receptors, and miRNAs inside vesicles to others targets. All these recent results ask important questions about cell-to-cell communication mediated by miRNAs, and raise the possibility that a yet undiscovered biological information transduction system exists, and could be important to explain many biological processes including development, differentiation, and stress response. In cardiovascular diseases, for example, the general decrease in circulating miRNAs detected in patients with CAD might be caused by a disregulation of this miRNA trafficking system in atherosclerotic lesions or in the infarcted myocardium.
6. MiRNAs: New biomarkers in vascular and cardiac diseases
Being instrumental players in the fine-tuning of gene regulation networks, microRNAs have significant diagnostic and prognostic value, as biomarkers of disease etiology and progression. Until recently, however, miRNA quantitation and usefulness as a biomarker was dependent on the availability of the pathological tissue. This was not a major setback for the diagnosis of cancer, where biopsies were readily available in most cases, but proved to be serious concern when dealing with heart or vascular pathologies. Very recently, these concerns were alleviated when several teams showed that miRNAs can be detected and precisely measured in human blood (eg [63,64]). These papers, showing a stable presence of miRNA in human plasma, came as a surprise. Indeed, any researcher having experience with RNA work considers ribonucleic acids as fragile and unable to survive in a liquid like serum which contains a wealth of specific and non-specific degrading enzymes.
Stephanie Dimmeler’s pioneer studies show that miRNA can be detected in the serum of patients with coronary artery diseases (CAD) and that their levels are altered in patient’s serum when compared to healthy counterparts  [65-66]. MiRNAs are thus prime candidates as novel non-invasive biomarkers in cardiovascular diseases, which can be measured in routine clinical diagnosis. The main question here is which endogenous referent genes to use as this is instrumental in qPCR. In cardiovascular disease studies, various endogenous circulating miRNAs (eg miR-17-5p, miR-454, U6 or RNU6b) have been used for normalization of circulating miRNAs, but the use of spiked-in miRNAs,
An important question is the exact localization of miRNAs in the bloodstream. They exist in a highly stable, extracellular form and are remarkably persistent in the RNase-rich environment of blood. The first model postulates that circulating miRNAs are protected by encapsulation in membrane-bound vesicles such as exosomes, phagosomes, apoptotic bodies…[65-66] Arroyo et al.  have however recently challenged this view: they used a combination of differential centrifugation and size-exclusion chromatography and showed that circulating miRNAs cofractionate mostly with protein complexes rather than with vesicles, in human plasma and serum. Even more surprising was the fact that the main miRNA binding partner was Ago2, the key effector protein of miRNA-mediated silencing, which is considered as a cytosolic protein. Ago2 seems to be one of the factors protecting circulating miRNAs from plasma RNases, since purified miRNAs, devoid of protein partners, were sensitive to RNase treatment. Figure 4 summarizes the different hypotheses that have been put forward to explain how miRNAs can be secreted and exported in human blood.
Goren et al.  have very recently published that four miRNAs, miR-22, miR-92b, miR-320a and miR-423-5p were significantly increased in the serum of patients with heart failure. By relying on a signature derived from the expression of these miRNAs, the authors were able to discriminate between systolic heart failure patients and healthy controls with a sensitivity and specificity of 90%. Moreover, there was a significant correlation with important clinical prognostic parameters such as an elevated serum natriuretic peptide and a wide QRS. Other recent papers have highlighted the interest of determining their levels in serum and other body fluids, including urine, feces and saliva [69-70]. This forebodes well for the increasing usefulness of specific miRNA expression as non-invasive biomarkers.
7. Potential of miRNAs as innovative drug targets
In the last decade, the increasing interest in small RNAs has triggered the arrival of innovative drug targets on the pharmaceutical market. Among these small RNAs, miRNAs provide perhaps the most promising new opportunities for developing new compounds, especially with the recent advances in anti-miRNA chemistry. On one hand, therapeutic nucleic acids can be administered using lentivirus-mediated antagomir expression, which induces a stable knock-down phenotype for a specific miRNA [71-72]. On the other hand, the vast majority of anti-miRs used in trials are in fact altered locked nucleic acids (LNA), also known as inaccessible RNA (reviewed in ). The canonic nucleic acid ribose sugar backbone is modified with an extra bridge connecting the 2' oxygen and 4' carbon . This conformation enhances base stacking and backbone pre-organization, which will significantly enhance the hybridization properties for the compounds. These poly-anionic molecules tend to distribute broadly but also to accumulate in liver, kidney and phagocytes. They are highly hydrophilic, with a molecular weight ranging from 2 to 6 kD. For the moment, routes of administration used are essentially intravenous and subcutaneous injections [75-76]. One has however got to keep in mind that developing innovative drugs is risky, represents a tremendous cost in resources, time, etc., and should not be undertaken lightly.
A first clinical trial, in this post-genome era, is under way in human patients affected by viral hepatitis C. Phase IIa results of this promising trial, focusing on the liver-specific miR-122 , aims to develop the related drug called Miravirsen, developed by Santaris Pharma A/S as a LNA antagomir, and thus to antagonize miR-122, which is instrumental for Hepatitis C virus C (HCV) infection. Langford et al.  had already shown in primates that a LNA-specific for miR-122 was able to suppress HCV viremia, with no evidence of viral resistance or side effects in the treated animals. These promising results are confirmed in humans and show that using an antagomir approach induces a decrease of the patient’s viral load, and that this revolutionary treatment is less toxic and more effective than current medicine (http://www.santaris.com/news/2011/11/05/santaris-pharma-phase-2a-data-miravirsen-shows-dose-dependent-prolonged-viral-reduct), perhaps due to the specificity brought by RNA strand complementarity.
Concerning cardiovascular diseases, we will now focus on the expanding interest of miRNAs in cardiovascular molecular medicine, and the various studies that have been undertaken, on animal models, for the time being.
The important role of the miR-29 family of microRNAs has already been evoked in this chapter (see subchapter V). A promising study dealt with their effects in two murine models of abdominal aortic aneurysm (AAA) (porcine pancreatic elastase [PPE] infusion model in C57BL/6 mice and the AngII infusion model in ApoE-/- mice). Antagomirs against miR-29b was administered
Matkovich et al.  have shown that over-expression of miR-133a in the heart of transgenic mice prevented TAC-associated miR-133a downregulation and improved myocardial fibrosis and diastolic function. In another, more exotic, model, Yin et al.  have shown that miR-133 restricts injury-induced cardiomyocyte proliferation.
Very recently, miR-33, although not specific for cardiac or vascular tissues, has gained a lot of attention in atherosclerosis treatment . Both miR-33a and miR-33b target the adenosine triphosphate-binding cassette transporter A1 (ABCA1), an important regulator of high-density lipoprotein (HDL) synthesis and reverse cholesterol transport in a murine model. Inhibiting miR-33 using two different methods (overexpression of dedicated lentiviral particles or injection of LNA antagomiRs) led to an up-regulation of ABCA1 and importantly to an increase of cholesterol influx and concomitant increase in the levels of HDL, and thus of atheroprotective effects. These authors show thus clearly that increasing HDL levels in Mouse via miR-33-specific antagomiRs promotes reverse cholesterol transport and suggest that it may be a promising strategy to induce atherosclerosis regression. Several months later, the same team published similar results in primates, more precisely African green monkeys . In addition to the beneficial effects already detected in Mouse, the authors showed a strong decrease of plasma levels of very-low-density lipoprotein (VLDL)-associated triglycerides. This difference can tentatively be attributed to the presence of miR-33b in the SREBF1 gene of medium and large mammals and its absence in rodents. Pharmacological use of antagomiRs specific for miR-33a and miR-33b is thus able to markedly raise plasma HDL and lower VLDL triglyceride levels and therefore a promising therapeutic strategy to treat dyslipidaemias, and their induced cardiac consequences in human patients.
8. In conclusion: MicroRNAs, a bright future?
In the last decade, many advances have been made to decipher miRNA roles in cardiovascular development and pathogenesis. New methods have been developed in order to use them as innovative biomarkers in diagnostics, and as groundbreaking drugs in pharmacological treatments. A first, promising, clinical trial in humans is in progress right now. However, many questions remain still to be answered. Each miRNA targets up to one hundred mRNA targets, which poses significant challenges to the identification, and specific targeting, of the mRNAs that are relevant to a particular pathological process. On the other hand, this problem could also become a solution, since it is now clear that a particular family of miRNAs is associated with the same disease type . So it could prove more efficient to target a predefined network of related miRNAs rather than a single one .
With the current pace of evolution in understanding the basic ways of miRNA action in cardiovascular development and disease, one can safely trust that these small molecules will still amaze us with more revelations in the near and not so near future.Acknowledgement
This work was funded by grants from the Picardie Regional Council (MARNO-MPCC and
Bartel DP. MicroRNAs: target recognition and regulatory functions.Cell 2009 136 2 215 233
Methods Mol Biol Gommans W. M. Berezikov E. Controlling mi. R. N. A. regulation in. disease 2012 822 1
Rangrez A. Y. Massy Z. A. Metzinger Le Meuth. V. Metzinger L. mi R-1. mi R-14. Molecular keys. to switch. the phenotype. of vascular. smooth muscle. cells Circulation. Cardiovascular Genetics. 2011 4 2 197 205
Small EM, Frost RJ, Olson EN.MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010 121 8 1022 1032
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation Thum T. Galuppo P. Wolf C. Fiedler J. Kneitz S. van Laake L. W. Doevendans P. A. Mummery C. L. Borlak J. Haverich A. Gross C. Engelhardt S. Ertl G. Bauersachs J. Micro R. N. 2007 116 3 258 267
Kim VN. MicroRNA biogenesis: coordinated cropping and dicing.Nature Reviews Molecular and Cellular Biology 2005 6 5 376 385
The role of the precursor structure in the biogenesis of microRNA. Cellular and Molecular Life Sciences Starega-Roslan J. Koscianska E. Kozlowski P. Krzyzosiak W. J. 2011 68 17 2859 2871
Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature Guo H. Ingolia N. T. Weissman J. S. Bartel D. P. 2010 466 7308 835 40
Forman JJ, Coller HA.The code within the code: microRNAs target coding regions; Cell Cycle 2010 9 8 1533 1541
New class of microRNA targets containing simultaneous 5’-UTR and 3’-UTR interaction sites, Genome Research Lee I. Ajay S. S. Yook J. I. Kim H. S. Hong S. H. Kim N. H. Dhanasekaran S. M. Chinnaiyan A. M. BD Athey 2009 19 7 1175 1183
Molecular Cell Shin C. Nam J. W. Farh K. K. Chiang H. R. Shkumatava A. Bartel D. P. Expanding the. micro R. N. A. targeting code. functional sites. with centered. pairing 2010 38 6 789 802
Current Protocols in Bioinformatics Griffiths-Jones S. mi R. Base micro. R. N. A. sequences annotation 2010Chapter 12 Unit 12 9 1 10
Nature Reviews in Genetics Berezikov E. Evolution of. micro R. N. A. diversity regulation in. animals 2011 12 12 846 860
Heart Lung Circulation Bernardo B. C. Charchar F. J. Lin R. C. Mc Mullen J. R. A. micro R. N. A. guide for. clinicians basic scientists. background experimental techniques. 2012 21 3 131 42
Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics Chen Y. Gelfond J. A. Mc Manus L. M. Shireman P. K. 2009
Nature Methods Xie J. Ameres S. L. Friedline R. Hung J. H. Zhang Y. Xie Q. Zhong L. Su Q. He R. Li M. Li H. Mu X. Zhang H. Broderick J. A. Kim J. K. Weng Z. Flotte T. R. Zamore P. D. Gao G. Long-term efficient. inhibition of. micro R. N. A. function in. mice using. r. A. A. V. vectors 2012 9 4 403 409
Smooth muscle miRNAs are critical for post-natal regulation of blood pressure and vascular function, PLoS One Albinsson S. Skoura A. Yu J. Di Lorenzo A. Fernandez-Hernando C. Offermanns S. Miano J. M. Sessa W. C. 2011e18869.
Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. Journal of Clinical Investigation Boettger T. Beetz N. Kostin S. Schneider J. Kruger M. Hein L. Braun T. 2009 119 9 2634 2647
Nature Cordes K. R. Sheehy N. T. White M. P. Berry E. C. Morton S. U. Muth A. N. Lee T. H. Miano J. M. Ivey K. N. Srivastava D. mi R-1. mi R-1. regulate smooth. muscle cell. fate plasticity 2009 460 7256 705 710
The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differentiation Elia L. Quintavalle M. Zhang J. Contu R. Cossu L. Latronico M. V. Peterson K. L. Indolfi C. Catalucci D. Chen J. Courtneidge S. A. Condorelli G. 2009 16 12 1590 1598
Affinity purification of microRNA-133a with the cardiac transcription factor, Hand2. Proceedings of the National Academy of Sciences U S A Vo N. K. Dalton R. P. Liu N. Olson E. N. Goodman R. H. 2010 107 45 19231 19236
Down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. Journal of Biological Chemistry Davis-Dusenbery B. N. Chan M. C. Reno K. E. AS Weisman Layne. MD Lagna G. Hata A. 2011 286 32 28097 28110
Circulation Research Torella D. Iaconetti C. Catalucci D. Ellison G. M. Leone A. Waring C. D. Bochicchio A. Vicinanza C. Aquila I. Curcio A. Condorelli G. Indolfi C. Micro R. N. A-1 controls vascular. smooth muscle. cell phenotypic. switch in. vitro vascular remodeling. in vivo. 2011 109 8 880 893
Miano JM, Small EM. MicroRNA133a: a new variable in vascular smooth muscle cell phenotypic switching.Circulation Research 2011 109 8 825 827
Proceedings of the National Academy of Sciences U S A BD Harfe Mc Manus. M. T. Mansfield J. H. Hornstein E. Tabin C. J. The R. Nase I. I. I. enzyme Dicer. is required. for morphogenesis. but not. patterning of. the vertebrate. limb 2005 102 31 10898 10903
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Development Kanellopoulou C. Muljo S. A. Kung A. L. Ganesan S. Drapkin R. Jenuwein T. Livingston D. M. Rajewsky K. 2005 19 4 489 501
Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. Journal of Dermatological Science Cheng B. Liu H. W. Fu X. B. Sun T. Z. Sheng Z. Y. 2007 45 3 193 201
Journal of Biological Chemistry Boucher J. M. Peterson S. M. Urs S. Zhang C. Liaw L. The mi. R-143/1 cluster is. a. novel transcriptional. target of. Jagged- Notch signaling. in vascular. smooth muscle. cells 2011 286 32 28312 28321
Genes Development Xin M. Small E. M. Sutherland L. B. Qi X. Mc Anally J. Plato C. F. Richardson J. A. Bassel-Duby R. Olson E. N. Micro R. N. As mi R-1. mi R-1. modulate cytoskeletal. dynamics responsiveness of. smooth muscle. cells to. injury 2009 23 18 2166 2178
Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nature Cell Biology Hergenreider E. Heydt S. Treguer K. Boettger T. Horrevoets A. J. Zeiher A. M. Scheffer M. P. AS Frangakis Yin. X. Mayr M. Braun T. Urbich C. Boon R. A. Dimmeler S. 2012 14 3 249 256
Journal of Biological Chemistry, Davis B. N. Hilyard A. C. Nguyen P. H. Lagna G. Hata A. Induction of. micro R. N. A-2 by platelet-derived. growth factor. signaling is. critical for. modulation of. vascular smooth. muscle phenotype. 2009 284 6 3728 3738
Circulation Research Ji R. Cheng Y. Yue J. Yang J. Liu X. Chen H. Dean D. B. Zhang C. Micro R. N. A. expression signature. antisense-mediated depletion. reveal an. essential role. of Micro. R. N. A. in vascular. neointimal lesion. formation 2007 100 11 1579 1588
MicroRNAs in vascular and metabolic disease. Circulation Research Zampetaki A. Mayr M. Micro R. N. 2012 110 3 508 522
Regulation of the Le Sage C. Nagel R. Egan D. A. Schrier M. Mesman E. Mangiola A. Anile C. Maira G. Mercatelli N. Ciafre S. A. Farace M. G. Agami R. 27Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation, Embo Journal 2007
Circulation Research Liu X. Cheng Y. Zhang S. Lin Y. Yang J. Zhang C. A. necessary role. of mi. R-2 mi R-2. in vascular. smooth muscle. cell proliferation. neointimal hyperplasia. 2009 104 4 476 487
Biogenesis and regulation of cardiovascular microRNAs. Circulation Research Bauersachs J. Thum T. 2011 109 3 334 347
microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart, Genes Development Liu N. Bezprozvannaya S. Williams A. H. Qi X. Richardson J. A. Bassel-Duby R. Olson E. N. micro R. N. 2008 22 23 3242 3254
Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. Journal of Molecular and Cellular Cardiology Tatsuguchi M. Seok H. Y. Callis T. E. Thomson J. M. Chen J. F. Newman M. Rojas M. Hammond S. M. Wang D. Z. 2007 42 6 1137 1141
Nature Medicine Yang B. Lin H. Xiao J. Lu Y. Luo X. Li B. Zhang Y. Xu C. Bai Y. Wang H. Chen G. Wang Z. The muscle-specific. micro R. N. A. mi R. regulates cardiac. arrhythmogenic potential. by targeting. G. J. A. K. C. N. J. 2007 13 4 486 491
Terentyev D. Belevych A. E. Terentyeva R. MM Martin Malana. G. E. Kuhn D. E. Abdellatif M. DS Feldman Elton. T. S. Gyorke S. mi R. overexpression enhances. Ca(2 release promotes cardiac. arrhythmogenesis by. targeting P. P. A. regulatory subunit. B56alpha Ca causing M. K. I. I-dependent hyperphosphorylation. of Ry. R. Circulation Research. 2009 104 4 514 521
Cardiology Bostjancic E. Zidar N. Stajer D. Glavac D. Micro R. N. As mi R-. mi R-133a. mi R-133b. mi R-2. are dysregulated. in human. myocardial infarction. 2010 115 3 163 169
Cell Stem Cell, Ivey K. N. Muth A. Arnold J. King F. W. Yeh R. F. Fish J. E. Hsiao E. C. Schwartz R. J. Conklin B. R. Bernstein H. S. Srivastava D. Micro R. N. A. regulation of. cell lineages. in mouse. human embryonic. stem cells. 2008 2 3 219 229
Carè A. Catalucci D. Felicetti F. Bonci D. Addario A. Gallo P. Bang M. L. Segnalini P. Gu Y. Dalton N. D. Elia L. Latronico M. V. Hoydal M. Autore C. MA Russo Dorn. G. W. 2nd Ellingsen O. Ruiz-Lozano P. Peterson K. L. Croce C. M. Peschle C. Condorelli G. Micro R. N. A-1 controls cardiac. hypertrophy Nature. Medicine 2007 13 5 613 618
Biochemical and Biophysical Research Communications Horie T. Ono K. Nishi H. Iwanaga Y. Nagao K. Kinoshita M. Kuwabara Y. Takanabe R. Hasegawa K. Kita T. Kimura T. Micro R. N. A-1 regulates the. expression of. G. L. U. T. by targeting. K. L. F. is involved. in metabolic. control in. cardiac myocytes. 2009 389 2 315 320
Nature Thum T. Gross C. Fiedler J. Fischer T. Kissler S. Bussen M. Galuppo P. Just S. Rottbauer W. Frantz S. Castoldi M. Soutschek J. Koteliansky V. Rosenwald A. MA Basson Licht. JD Pena J. T. Rouhanifard S. H. Muckenthaler M. U. Tuschl T. Martin G. R. Bauersachs J. Engelhardt S. Micro R. N. A- contributes to. myocardial disease. by stimulating. M. A. P. kinase signalling. in fibroblasts. 2008 456 7224 980 984
MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? American Journal of Pathology Cheng Y. Ji R. Yue J. Yang J. Liu X. Chen H. Dean D. B. Zhang C. Micro R. N. 2007 170 6 1831 1840
Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. Journal of Clinical Investigation Patrick D. M. Montgomery R. L. Qi X. Obad S. Kauppinen S. Hill J. A. van Rooij E. Olson E. N. 2010 120 11 3912 3916
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National Academy of Sciences U S A van Rooij E. Sutherland L. B. Thatcher J. E. Di Maio J. M. Naseem R. H. Marshall W. S. Hill J. A. Olson E. N. 2008 105 35 13027 13032
MicroRNAs differentially expressed in postnatal aortic development downregulate elastin via 3’ UTR and coding-sequence binding sites. PLoS One CE Ott Grunhagen. J. Jager M. Horbelt D. Schwill S. Kallenbach K. Guo G. Manke T. Knaus P. Mundlos S. Robinson P. N. Micro R. N. 2011e16250.
Jones JA, Stroud RE, O’Quinn EC, Black LE, Barth JL, Elefteriades JA, Bavaria JE, Gorman JH 3rd, Gorman RC, Spinale FG, Ikonomidis JS. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction.Circulation Cardiovascular Genetics 2011 4 6 605 613
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. Journal of Clinical Investigation Callis T. E. Pandya K. Seok H. Y. Tang R. H. Tatsuguchi M. Huang Z. P. Chen J. F. Deng Z. Gunn B. Shumate J. MS Willis Selzman. C. H. Wang D. Z. Micro R. N. 2009 119 9 2772 2786
Control of stress-dependent cardiac growth and gene expression by a microRNA. Science van Rooij E. Sutherland L. B. Qi X. Richardson J. A. Hill J. Olson E. N. 2007 316 5824 575 579
Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Research Wang K. Zhang S. Weber J. Baxter D. Galas D. J. 2010 38 20 7248 7259
Cell Cesana M. Cacchiarelli D. Legnini I. Santini T. Sthandier O. Chinappi M. Tramontano A. Bozzoni I. A. long noncoding. R. N. A. controls muscle. differentiation by. as functioning a. competing endogenous. R. N. A. 2011 147 4 358 69
Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature Wang Z. Wang D. Z. Hockemeyer D. Mc Anally J. Nordheim A. Olson E. N. 2004 428 6979 185 189
Chen J. Yin H. Jiang Y. Radhakrishnan S. K. Huang Z. P. Li J. Shi Z. Kilsdonk E. P. Gui Y. Wang D. Z. Zheng X. L. Induction of. micro R. N. A. by myocardin. in smooth. muscle cells. inhibits cell. proliferation Arterioscleris. Thrombosis Vascular. Biology 2011 31 2 368 75
Repression of versican expression by microRNA-143. Journal of Biological Chemistry Wang X. Hu G. Zhou J. 2010 285 30 23241 23250
Regulation of cardiac microRNAs by serum response factor. Journal of Biomedical Science Zhang X. Azhar G. Helms S. A. Wei J. Y. 2011
Journal of Biological Chemistry, Long X. Miano J. M. Transforming growth. factor-beta . T. G. F-beta utilizes distinct. pathways for. the transcriptional. activation of. micro R. N. A. 143/1 in human. coronary artery. smooth muscle. cells 2011 286 34 30119 30129
Journal of Cell Biology Hirai H. Verma M. Watanabe S. Tastad C. Asakura Y. Asakura A. Myo D. regulates apoptosis. of myoblasts. through micro. R. N. A-mediated down-regulation. of Pax. 2010 191 2 347 365
Cell adhesion-dependent control of microRNA decay. Molecular Cell Kim Y. K. Yeo J. Ha M. Kim B. Kim V. N. 2011 43 6 1005 1014
Wang G. K. Zhu J. Q. Zhang J. T. Li Q. Li Y. He J. Qin Y. W. Jing Q. Circulating micro. R. N. A. a. novel potential. biomarker for. early diagnosis. of acute. myocardial infarction. in humans. European Heart. Journal 2010 31 6 659 666
Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One MJ Lodes Caraballo. M. Suciu D. Munro S. Kumar A. Anderson B. 2009e6229.
Wang K. Zhang S. Marzolf B. Troisch P. Brightman A. Hu Z. Hood L. E. Galas D. J. Circulating micro. R. N. As potential biomarkers. for drug-induced. liver injury. Proceedings of. the National. Academy of. Sciences U. S. A. 2009 106 11 4402 4407
Transcoronary concentration gradients of circulating microRNAs. Circulation De Rosa S. Fichtlscherer S. Lehmann R. Assmus B. Dimmeler S. Zeiher A. M. 2011 124 18 1936 1944
Circulating microRNAs in patients with coronary artery disease. Circulation Research Fichtlscherer S. De Rosa S. Fox H. Schwietz T. Fischer A. Liebetrau C. Weber M. Hamm C. W. Roxe T. Muller-Ardogan M. Bonauer A. Zeiher A. M. Dimmeler S. 2010 107 5 677 684
Proceedings of the National Academy of Sciences U S A JD Arroyo Chevillet. J. R. Kroh E. M. Ruf I. K. Pritchard C. C. Gibson D. F. Mitchell P. S. Bennett C. F. Pogosova-Agadjanyan E. L. Stirewalt D. L. Tait J. F. Tewari M. Argonaute complexes. carry a. population of. circulating micro. R. N. As independent of. vesicles in. human plasma. 2011 108 12 5003 5008
Serum levels of microRNAs in patients with heart failure. European Journal of Heart Failure Goren Y. Kushnir M. Zafrir B. Tabak S. BS Lewis Amir. O. 2012 14 2 147 154
Koga Y. Yasunaga M. Takahashi A. Kuroda J. Moriya Y. Akasu T. Fujita S. Yamamoto S. Baba H. Matsumura Y. Micro R. N. A. expression profiling. of exfoliated. colonocytes isolated. from feces. for colorectal. cancer screening. Cancer Prevention. Research . Phila 2010 3 11 1435 1442
Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus Wang G. Tam L. S. Li E. K. Kwan B. C. Chow K. M. Luk C. C. Li P. K. Szeto C. C. 2011 20 5 493 500
Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Research Scherr M. Venturini L. Battmer K. Schaller-Schoenitz M. Schaefer D. Dallmann I. Ganser A. Eder M. 2007e149.
Methods in Molecular Biology Surdziel E. Eder M. Scherr M. Lentivirus-mediated antagomir. expression 2010 667 237
Lennox KA, Behlke MA.Chemical modification and design of anti-miRNA oligonucleotides. Gene Therapy 2011 18 12 1111 1120
Synthesis of 2′-O,4′-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fixed C3’-endo sugar puckering. Tetrahedron Letters Obika S. Nanbu D. Hari Y. Morio K. I. In Y. Ishida T. Imanishi T. 1997 38 50 8735 8738
Nature Baker M. R. N. A. interference Homing. in on. delivery 2010 464 7292 1225 1228
Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development, Biochemical Pharmacology Gambari R. Fabbri E. Borgatti M. Lampronti I. Finotti A. Brognara E. Bianchi N. Manicardi A. Marchelli R. Corradini R. 2011 82 10 1416 1429
Jopling C. Liver-specific micro. R. N. A-12 Biogenesis function R. N. A. Biology 2012Epub ahead of print].
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, Lanford R. E. Hildebrandt-Eriksen E. S. Petri A. Persson R. Lindow M. ME Munk Kauppinen. S. Orum H. 2010 327 5962 198 201
Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. Journal of Clinical Investigation Maegdefessel L. Azuma J. Toh R. Merk D. R. Deng A. Chin J. T. Raaz U. Schoelmerich A. M. Raiesdana A. Leeper N. J. Mc Connell M. V. Dalman R. L. Spin J. M. Tsao P. S. 2012 122 2 497 506
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circulation Research Matkovich S. J. Wang W. Tu Y. Eschenbacher W. H. Dorn L. E. Condorelli G. Diwan A. Nerbonne J. M. Dorn G. W. 2nd Micro. R. N. 2010 106 1 166 75
Regulation of zebrafish heart regeneration by miR-133. Developmental Biology Yin V. P. Lepilina A. Smith A. Poss K. D. 2012 365 2 319 327
Journal of Clinical Investigation Rayner K. J. Sheedy F. J. Esau C. C. Hussain F. N. Temel R. E. Parathath S. van Gils J. M. Rayner A. J. Chang A. N. Suarez Y. Fernandez-Hernando C. Fisher E. A. Moore K. J. Antagonism of. mi R-. in mice. promotes reverse. cholesterol transport. regression of. atherosclerosis 2011 121 7 2921 2931
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature Rayner K. J. Esau C. C. Hussain F. N. Mc Daniel A. L. Marshall S. M. van Gils J. M. Ray T. D. Sheedy F. J. Goedeke L. Liu X. Khatsenko O. G. Kaimal V. Lees C. J. Fernandez-Hernando C. Fisher E. A. Temel R. E. Moore K. J. 2011 478 7369 404 407
Discovering dysfunction of multiple microRNAs cooperation in disease by a conserved microRNA co-expression network, PLoS One Xiao Y. Xu C. Guan J. Ping Y. Fan H. Li Y. Zhao H. Li X. 2012e32201.
Kasinski AL, Slack FJ. Epigenetics and genetics.MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer, 2011 11 12 849 864